Design Therapeutics (DSGN)
Develops GeneTAC small molecules that tune disease-causing gene expression.
Something off on this page? Send us feedback.
Develops GeneTAC small molecules for inherited genetic diseases. Its clinical portfolio spans Friedreich ataxia, Fuchs endothelial corneal dystrophy, and myotonic dystrophy type 1, while the business relies on clinical development and external manufacturing.
Develops GeneTAC small molecules designed to dial disease-causing gene expression up or down. Its clinical portfolio includes DT-216P2 for Friedreich ataxia, DT-168 for Fuchs endothelial corneal dystrophy, and DT-818 for myotonic dystrophy type 1.
Operates as a clinical-stage platform company, with drug candidates advancing through clinical studies rather than commercial product sales. Development depends on regulatory clearance and specialized external research and manufacturing capacity.
Does not operate cGMP manufacturing facilities and relies on third-party manufacturers and suppliers for GeneTAC materials. A formulation adjustment for DT-216 and a later FDA clinical hold on DT-216P2 demonstrate how clinical and regulatory requirements can alter program timing.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| May 4, 2026 | Oppenheimer | Reiterate | Rating: —Target: $18 | Target: $21 |
| Apr 29, 2026 | Piper Sandler | Target | Target: $12 | Target: $20 |
| Jan 7, 2026 | Oppenheimer | Target | Target: — | Target: $18 |
| Dec 3, 2025 | Craig-Hallum | Target | Target: — | Target: $15 |
| Dec 3, 2025 | Leerink Partners | Upgrade | Target: — | Target: $14 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $207.4M · Total debt $2.0M · Total assets $215.1M · Shareholders' equity $201.9M
- Revenue
- $0
- Operating income
- −$22.2M
- Net income
- −$20.2M
No dividends on record.
| Institutions | ≈ 69.57% | 43.54M shares | |
|---|---|---|---|
| 141 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 28.69% | 17.95M shares | |
| 4 holders · as of Mar 11, 2026 | |||
| Strategic holders | 17.86% | 11.18M shares | |
| 3 holders · as of Feb 7, 2025 | |||
| Adds to | 116.12% | ||
62.58M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 116.12%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
of 5 PagesInsider | 12.25% | 7.67M | filed Feb 9, 2022 |
Simeon George1,2Insiderdirector | 10.56% | 6.61M | filed Mar 11, 2026 |
Sr One Capital Management, LPInstitution | 10.43% | 6.53M | as of Jun 30, 2026 |
Sirenia Capital Management LPInstitution | 9.53% | 5.96M | filed Aug 14, 2026 |
Light Irrevocable Trust #1 dated April 22, 20193,4Strategic10 percent owner | 6.13% | 3.83M | filed Feb 7, 2025 |
- Simeon George's transaction reports restate only vehicles that traded; the 2026 ownership statement (6.61M) is used instead.
- Simeon George reports a block also reported by Sr One Capital Management, LP; it is counted once, under Sr One Capital Management, LP.
- Light Irrevocable Trust #1 dated April 22, 2019's transaction reports restate only vehicles that traded; the 2025 ownership statement (3.83M) is used instead.
- Light Irrevocable Trust #1 dated April 22, 2019 reports a block also reported by Simeon George; it is counted once, under Simeon George.
Insider tradesForm 4
No open-market trades in the last 12 months.
- Biogen
Approved FA therapy with established treatment access
- Larimar Therapeutics
Frataxin-replacement candidate advancing toward registration
- Dyne Therapeutics
Advanced DMPK-lowering therapy in global DM1 development
- PTC Therapeutics
FA program preparing an additional registration-supporting study
- Sarepta Therapeutics
Licensed DMPK-targeting siRNA in Phase 1/2 DM1 development
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Design Therapeutics | $12.63 | −4.07% | $821.9M | — | — | — | — |
| Biogen | $224.81 | −0.25% | $33.30B | 39.9 | 17.0 | 3.3 | +3.4% |
| Larimar Therapeutics | $3.76 | −1.57% | $396.8M | — | — | — | — |
| Dyne Therapeutics | $16.55 | −3.44% | $3.20B | — | — | — | — |
| PTC Therapeutics | $63.99 | −2.99% | $5.51B | — | 51.7 | 5.5 | +101.6% |
| Sarepta Therapeutics | $19.36 | −6.97% | $2.20B | — | 33.7 | 1.1 | −34.3% |
| Median | 39.9 | 33.7 | 3.3 | +3.4% |